Caption Management 13F: New $23M Stake in COMPASS Pathways (CMPS)

Caption Management Establishes COMPASS Position

Caption Management initiated a new stake in COMPASS Pathways plc (NASDAQ: CMPS) during the quarter ending May 15, 2026, according to its latest Form 13F filing with the Securities and Exchange Commission. The investment manager bought 1,610,130 shares of the healthcare company, establishing a brand-new holding. The regulatory filing valued the new position at approximately $22.78 million.

Because 13F filings are backward-looking documents, they show a fund's holdings as of the end of the reporting period. They do not necessarily represent Caption Management's active, real-time portfolio today.

Growth in the Biotech Space

This new investment by Caption Management aligns with other notable institutional interest in the company. For example, during the same general timeframe, RTW Investments also increased its exposure to the biotechnology firm, boosting its holdings by 21.4% with the addition of 1.88 million shares. This collective institutional interest highlights growing attention on the mental health treatment developer.

COMPASS Pathways Stock Performance

COMPASS Pathways shares closed at $15.19 on the trading day prior to this writing, and on Sunday, the stock traded at $14.15. The stock has been trading comfortably above its 50-day moving average of $13.26 and its 200-day moving average of $9.63. Over the past year, the company's shares have fluctuated between a low of $4.88 and a high of $15.87.

Recent Earnings and Financial Health

COMPASS Pathways reported an EPS of -$3.79 for its most recent fiscal period. The company currently has no meaningful P/E ratio because it is not yet profitable, which is common for clinical-stage biotechnology firms. The company's quick ratio stands at 1.221, and its debt-to-equity ratio is 64.623. Investors are looking forward to the company's next earnings report, which is expected to be released on November 3, 2026.

Wall Street Analyst Updates

Several research firms have updated their views on the stock recently. On August 7, 2026, HC Wainwright & Co. maintained its buy rating and set a $65.00 price target. The previous day, August 6, 2026, Morgan Stanley maintained its overweight rating with an $18.00 target, while RBC Capital maintained its outperform rating with a target of $21.00. B. Riley Securities also kept its buy rating with a target of $22.00 on August 6, 2026.

Earlier in the summer, on July 27, 2026, Wells Fargo initiated coverage on COMPASS Pathways with an equal-weight rating and a $13.00 price target. On July 8, 2026, Evercore ISI Group upgraded the stock to outperform with a $21.00 target, and Stifel kept its buy rating with a target of $21.00. Overall, the company has 16 analyst opinions, resulting in a strong buy consensus and a mean target price of $23.75.

About COMPASS Pathways

COMPASS Pathways plc is a biotechnology firm that focuses on developing new pathways for mental health care. The London-headquartered company is primarily known for developing COMP360, a proprietary psilocybin therapy. This therapy is currently in Phase III clinical trials for treatment-resistant depression, as well as Phase II trials for other conditions, including post-traumatic stress disorder and anorexia nervosa.

What's Ahead for COMPASS Pathways plc

With major institutional funds like Caption Management and RTW Investments backing the stock, market observers will likely keep a close eye on the company's upcoming Phase III trial progress. The clinical results for COMP360 and the upcoming November 3, 2026, earnings release are the next key milestones to watch.